Research Topics
Genomes and Genes | K KajinamiSummaryAffiliation: Kanazawa Medical University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatinKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
Atherosclerosis 175:287-93. 2004..The other ABCG5/G8 polymorphisms did not show any significant interactions with the CYP7A1 polymorphism. We conclude that the ABCG8 H19 and CYP7A1 C-204 alleles appear to interact in a dose-dependent manner on atorvastatin response...- [Genetic testing and gene-based testing for hyperlipidemia and lipid metabolism disorders]Kouji Kajinami
Department of Cardiology, Kanazawa Medical University
Nippon Rinsho 63:301-7. 2005 - Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitorKouji Kajinami
Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi 920 0293, Japan
Cardiovasc Drug Rev 21:199-215. 2003..The efficacy and safety of higher dose treatment, as well as its long-term effects in the prevention of coronary artery disease, should be further investigated... - Cholesterol absorption inhibitors in development as potential therapeuticsKouji Kajinami
Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi, Kahoku gun 920 0293, Japan
Expert Opin Investig Drugs 11:831-5. 2002..This approach in the treatment of lowering cholesterol appears to play a more significant role in the clinical field of atherosclerotic vascular disease... - Statin pharmacogenomics: what have we learned, and what remains unanswered?Kouji Kajinami
Department of Cardiology, Kanazawa Medical University, Uchinada, Japan
Curr Opin Lipidol 16:606-13. 2005..The purpose of this review is to summarize recent progress in the research for exploring genetic determinants of clinical efficacy and safety of statin therapy... - Statin response and pharmacokinetics variantsKouji Kajinami
Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
Expert Opin Pharmacother 6:1291-7. 2005..Future studies using these approaches could provide more striking evidence, which may be sufficient to justify genetic analysis regarding pharmacokinetic variants in the clinical practice of statin therapy... - A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatinKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, USA
Atherosclerosis 180:407-15. 2005..We concluded that the CYP7A1 A-204C promoter variant was associated with poor response to atorvastatin, which were additively enhanced by common variants in another locus, APOE... - Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemiaKouji Kajinami
Department of Cardiology, Kanazawa Medical University, Daigaku, Uchinada machi, Japan
Am J Cardiol 92:1113-6. 2003..The serial changes in 3 markers were favorable-increased bone formation markers and unchanged bone resorption marker-but the changes occurred only in patients with pretreatment vitamin D levels >50 pg/ml... - Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphismKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
Atherosclerosis 178:331-8. 2005.... - ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatinKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, MA, USA
J Lipid Res 45:653-6. 2004..These results suggest that, in patients with hypercholesterolemia, the ABCG8 D19H variant is associated with greater LDLC-lowering response to atorvastatin therapy... - Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific mannerKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
Am J Cardiol 93:1046-50. 2004..Also, haplotype determination combined with these polymorphisms identified a subgroup that showed a striking response to treatment, which was not defined by a single polymorphism... - Imbalance of sex hormone levels in men with coronary artery diseaseKouji Kajinami
Department of Cardiology, Kanazawa Medical University, Uchinada, Japan
Coron Artery Dis 15:199-203. 2004..The aim of the study was to investigate the potential role of sex hormones in coronary atherosclerosis... - Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementKouji Kajinami
Department of Cardiology, Kanazawa Medical University, 1 1 Daigaku, Uchinada 920 0293, Japan
Atherosclerosis 177:219-34. 2004.... - NK-104: a novel synthetic HMG-CoA reductase inhibitorK Kajinami
Department of Cardiology, Kanazawa Medical University, Daigaku 1 1, Uchinada machi, Kahoku gun 920 0293, Japan
Expert Opin Investig Drugs 9:2653-61. 2000..NK-104 can provide a new and potentially superior therapeutic agent when compared with currently available other statins. Randomised controlled clinical trials to assess the long-term effects of this new statin on CAD would be required... - Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinasesK Kajinami
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
Mod Pathol 12:1174-80. 1999..These observations suggest that the MMP-TIMP system appears to play a significant role in the development of coronary ectasia.. - Pharmacogenomics of statin responsivenessKouji Kajinami
Department of Cardiology, Kanazawa Medical University, Daigaku Uchinada, Japan
Am J Cardiol 96:65K-70K; discussion 34K-35K. 2005..In the future, pharmacogenomic studies with a greater number of participants (>2,000 participants) should provide a better picture as to who is most likely and who is least likely to benefit from statin therapy... - Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study GroupH Mabuchi
Second Department of Internal Medicine, Kanazawa University School of Medicine, Japan
Am J Cardiol 82:1489-95. 1998..0088). It is concluded that LDL-apheresis is effective as treatment of CHD in FH heterozygotes, and may become the therapy of choice in severe types of FH... - Catalytically inactive lecithin: cholesterol acyltransferase (LCAT) caused by a Gly 30 to Ser mutation in a family with LCAT deficiencyX P Yang
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Ishikawa, Japan
J Lipid Res 38:585-91. 1997..Thus, the N-terminal domain appears crucial for enzymatic activity, in addition to the catalytically active consensus sequence of Gly179 to Gly183 and a putative sterol binding domain of Glu154 to Lys173... - Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthomaA Inazu
The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Takara machi, Japan
Atherosclerosis 145:405-13. 1999..In addition, higher levels of serum HDL3 triglyceride on lipid-lowering therapy (6 months) appear to be a common predictor of regression of Achilles' tendon xanthoma in the treatment with either pravastatin or probucol... - Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosisY Noji
The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
Clin Chem Lab Med 39:380-4. 2001.... - Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein geneX P Yang
Second Department of Internal Medicine, Department of General Medicine School of Medicine, Kanazawa University, Takara machi 13 1 Kanazawa, Ishikawa 920 8641, Japan
Arterioscler Thromb Vasc Biol 19:1950-5. 1999..999). Maternal isodisomy (maternal UPD 4q) was the basis for homozygosity of the MTP gene mutation in this patient... - Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study GroupK Kajinami
The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
Am J Cardiol 85:178-83. 2000.... - CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemiaKouji Kajinami
Lipid Research Laboratory, Division of Endocrinology Metabolism and Molecular Biology, Tufts New England Medical Center, Boston, Massachusetts, USA
Am J Cardiol 93:104-7. 2004.... - Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemiaA Inazu
Second Department of Internal Medicine, School of Medicine, University of Kanazawa, Japan
Horm Metab Res 24:284-8. 1992..334, p less than 0.05). These results indicate that the enhanced CETP activities may contribute to increase risk for developing atherosclerosis in FH by changing the distribution of cholesteryl ester in serum lipoproteins... - Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemiaM Kawashiri
The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
Am J Cardiol 86:840-5. 2000..Thus, the MTHFR mutation appears to accelerate the onset of CAD through elevation of plasma homocysteine levels in male heterozygous patients with FH... - Coronary calcification and coronary atherosclerosis: site by site comparative morphologic study of electron beam computed tomography and coronary angiographyK Kajinami
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
J Am Coll Cardiol 29:1549-56. 1997..We compared, on a site by site basis, the morphologic features of coronary calcifications determined by electron beam computed tomography (EBCT) and angiographically defined coronary atherosclerosis... - Role of a novel conduction pattern around the coronary sinus in cavotricuspid isthmus dependent right atrial flutterYoshio Yamaguchi
Department of Cardiology, Kanazawa Medical University School of Medicine, Ishikawa
J Cardiol 50:1-10. 2007.... - Serum apolipoproteins in heterozygous familial hypercholesterolemiaK Kajinami
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
Clin Chim Acta 211:93-9. 1992..34 +/- 0.07) was significantly lower than that in normal subjects (0.39 +/- 0.05). This difference might possibly be produced by an abnormal HDL metabolism of FH patients, a topic which remains to be elucidated by further investigation... - Therapeutic effects of LDL apheresis in the prevention of atherosclerosisK Kajinami
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
Curr Opin Lipidol 10:401-6. 1999..Since the mechanisms of clinical improvement caused by LDL apheresis extend beyond simple and drastic reduction of LDL cholesterol, further investigation based on recent vascular biological evidence is needed... - New variant of low density lipoprotein receptor gene. FH-TonamiK Kajinami
Second Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa, Japan
Arteriosclerosis 8:187-92. 1988..Neonatal diagnosis of FH in two fetuses from one family was possible through analyses of their LDLR genes in cord blood samples at delivery... - Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiencyBela F Asztalos
Lipid Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
J Lipid Res 45:448-55. 2004.... - Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemiaYoshihiro Noji
Molecular Genetics of Cardiovascular Disorders The Second Department of Internal Medicine, Vascular Medicine, Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
Atherosclerosis 163:157-64. 2002..As for the safety of pitavastatin, adverse reactions were observed in one case (4%) of subjective and objective symptoms. The effects of pitavastatin on TC and LDL-C were stable during long treatment of patients with heterozygous FH... - Effects of serum B vitamins on elevated plasma homocysteine levels associated with the mutation of methylenetetrahydrofolate reductase gene in JapaneseYuri Moriyama
Public Health Institute of Kochi Prefecture, Marunouchi 2 4 1, 780 0850, Kochi, Japan
Atherosclerosis 164:321-8. 2002..These findings suggest that elevated homocysteine levels among Japanese with the homozygous genotype for the MTHFR gene mutation can be modified efficiently by dietary supplement of vitamin B12 as well as folate... - Serum deoxyribonuclease I activity can be used as a novel marker of transient myocardial ischaemia: results in vasospastic angina pectoris induced by provocation testNorihiro Morikawa
Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan
Eur Heart J 28:2992-7. 2007....